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1 Isoxsuprine hydrochloride (ISX) is chemically
known as 4hydroxyα[1[(1methyl2phenoxy
ethyl)amino]ethyl]benzenemethanol hydrochloride
(Fig. 1). It is a vasodilator and causes direct relaxation
of vascular and uterine smooth muscle. Its use in the
treatment of premature labor and peripheral vasodila
tor is well known [1]. The USP XXI [2] adopts UV
spectrophotometric measurement of aqueous solution
of ISX at about 269 and 300 nm, while the British
pharmacopoeia [3] recommends a visual nonaqueous
titration using HClO4 and 1naptholbenzein as indi
cator.
Different analytical techniques reported for the
determination of ISX in both pharmaceuticals and
biological matrices include UV spectrophotometry [4,
5], ion selective electrode potentiometry [6], chemilu
minescence [7], high performance liquid chromatog
raphy (HPLC) [8–10], gas chromatography (GC)
[11], GCMS [12], LCMS [13], affinity chromatog
raphy [14], polarography [15] and fluorimetry [16].
Very recently, a comprehensive literature on visible
spectrophotometry method for the determination of
ISX has been compiled by same authors [17].
The reported methods are applicable to only over
microgram level. Assay procedure for the determina
tion of ISX in milligram level is of paramount impor
1  The article is published in the original.
tance in large scale analysis. Therefore, highly precise
stoichiometric reaction with a reagent possessing
antagonistic properties for the assay of pharmaceutical
using titrimetric procedure is still the choice of many
pharmacopoeias [18, 19]. There is only one titrimetric
procedure reported for ISX [3] and this scarcity could
be due to the nonvulnerability of the basic nitrogen
group. Although two electron releasing αmethyl
groups tend to raise the basicity of the amino group
present in ISX, because it is a hydrochloride salt, the
ISX exists in structure (b) form of Fig. 1 in solution
wherein the transfer of nonbonding electrons is
restricted, and hence the basicity of the amino group
gets decreased. The present work removes the proton
from the nitrogen utilizing the well known reaction
between mercuric acetate and hydrochloride (Fig. 2)
prior to the titration with perchloric acid in method A.
The ion association reaction of method B provides an
alternative to method A because they vary largely in
reaction selectivity. The selectivity of the acidimetric
method (method A) is based on differences in base
strength, whereas method B is specific for protonated
amine. Based on the difference in reaction selectivity,
both methods found diverse application in tablets,
injection and spiked human urine analyses. In order to
demonstrate high selectivity of method B, recovery of
ISX from the urine matrix was studied. Proposed
methods have been validated and found to be accurate
and precise.
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Abstract—Based on the nitrogenous base or quaternary ammonium moiety in isoxsuprine hydrochloride
(ISX), two highly accurate and selective titrimetric methods are proposed f or the determination of ISX in
spiked human urine, injection and tablets. Nonaqueous titration (Method A) involves removal of protonated
amine using mercuric acetate for enhanced basic nitrogen prior to titration with perchloric acid in an acetic
acid medium using crystal violet as indicator. Twophase titration (Method B) is based on ion association
complex formation between sodium lauryl sulphate (SLS) and protonated amine of ISX at pH 2.5 in aqueous
phase, end point being detected by change in dimethyl yellow color in chloroform layer. The methods are
applicable over the concentration range 2.0–20.0 mg and 1.0–10.0 mg for method A and method B, respec
tively. Calculations are based on 1 : 1 molar ratio, i.e., JSX : HClO4 for method A and ISX : SLS for method B,
owing to the presence of one nitrogen atom. Method A is applicable to the determination of ISX in
tablets whereas method B is applicable to spiked human urine, injection and tablets. The methods are vali
dated statistically by comparing the results with those of the reference method by applying the Student’s ttest
and Ftest. The accuracy was further ascertained by recovery studies via standard addition technique.
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APPARATUS AND MATERIAL
Elico 120 digital pH meter provided with a com
bined glassSCE electrode system was used to record
the pH. Distilled water was used throughout. All
chemicals used were analytical grade purchased from
Merck or Loba Chemie (Mumbai, India). A stock
standard solution of 2.0 and 1.0 mg/mL of pharma
ceutical grade ISX (Juggat Pharma, India) solution
was prepared in glacial acetic acid (Spec. gra. 1.05) for
method A and in water for method B, respectively. An
aqueous solution of ISX is reported to remain stable
for 323 days [20]. A 0.01 M perchloric acid (standard
ized against 0.01 M potassium dihydrogen phthalate),
0.5% crystal violet indicator and 3% w/v mercuric
acetate were prepared individually in glacial acetic
acid for method A. Chloroform (spec. gra. 1.48) and
absolute ethanol were used as such. A 0.01% w/v dim
ethyl yellow was prepared in absolute ethanol,
0.0035 M sodium lauryl sulfate was prepared in water,
and 2 M sulfuric acid was prepared by appropriately
diluting concentrated sulfuric acid (Spec. gra. 1.84)
with water, for use in method B.
Assay procedure. Method A. Different volumes (1–
10 mL) of standard solution containing 2 mg/mL ISX
were taken in a 100 mL titration flask and the volume
was made up to 10 mL with glacial acetic acid, fol
lowed by the addition of 3 mL of 3% mercuric acetate.
The solution was swirled for homogeneity before the
addition of two drops of crystal violet indicator and
titrated against standardized solution of 0.01 M per
chloric acid to a blue end point.
Method B. Varying aliquots (1–10 mL) of 1 mg/mL
standard ISX solution were accurately measured into a
100 mL beaker and the volume adjusted to 10 mL with
water. One drop (0.05 mL) of 2 M H2SO4 and 1 mL of
0.01% dimethyl yellow were added and mixed well.
Further, 10 mL of chloroform was added and the solu
tion was vigorously stirred on a magnetic stirrer till the
organic phase turned yellow. Then the solution was
titrated against 0.0035 M sodium lauryl sulfate upon
stirring continuously, until the organic layer turned
pink at the end point.
The amount of ISX in the aliquot was computed
from the following formula:
where S—volume of titrant consumed for sample,
mL, B—volume of titrant consumed for blank, mL,
Mw—relative molecular mass of drug, C—strength of
titrant, M, n—number of moles of titrant reacting
with one mole of ISX.
Procedure for tablets. Twenty tablets were weighed
accurately and ground into a fine powder. Four por
tions of the powder equivalent to 200 or 100 mg of ISX
were accurately weighed into a 100 mL volumetric
flask and extraction was done by shaking for half an
hour with 40 mL of solvent specified under each
method; then, the volume was diluted to the mark with
the respective solvent, mixed well and filtered using a
Whatman no. 42 filter paper. First 10 mL portion was
discarded and subsequent portion of the tablet extract
was subjected to titration by following the procedures
mentioned under each method.
Procedure for spiked human urine and injection.
5 mL of ISX free urine was added to the 5 mL aqueous
solution containing 5 mg of ISX in a 100 mL beaker.
The pH of the solution was brought to 2.5 by adding
2 M H2SO4 and subjected to titration by following the
procedure mentioned in Method B. Two ml of injec
tion solution containing 5 mg/2 mL was transferred
into a 100 mL beaker and volume made up to 10 mL
with water. The solution was subjected to titration by
following the procedure mentioned in method B. 
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Fig. 1. (a) Isoxsuprine hydrochloride; (b) Isoxsuprine hydrochloride in solution form.
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Fig. 2. Conversion to hydrochloride free form of ISX. 
JOURNAL OF ANALYTICAL CHEMISTRY  Vol. 67  No. 4  2012
NONAQUEOUS AND TWOPHASE TITRIMETRIC ASSAY 337
RESULTS AND DISCUSSION
Due to the nonleveling properties of organic
solvents, weak organic acids and bases are quantita
tively titrated against their antagonist reagents
based on the neutralization due to the formation of
a coordinate bond between an acid and a base.
Basicity of the secondary amino group, after treat
ment with mercuric acetate, present in ISX was
enhanced in glacial acetic acid which acts as a pro
togenic solvent and titrated as amine acetates with
perchloric acid.
The end point was detected by change of protolytic
equilibrium of the crystal violet indicator. Since atmo
spheric carbon dioxide interferes during the course of
the titration, a blank titration was performed to com
pensate. This method was unsuitable to the determi
nation of ISX in spiked urine sample and in injection.
This is due to the presence of nitrogenous base in urine
and the presence of more than 3% water as solvent in
injection solution.
The anionic surfactant, sodium lauryl sulphate,
forms ion association complex with cationic amino
group of ISX. The relatively neutral complex in the
form of an emulsion in aqueous phase gradually dis
solved in chloroform layer. The end point is detected
by indicator fulfilling two criteria. Indicator should
contain tertiary amino group and it should be a pH
indicator. The dimethyl yellow is widely used as a
twophase indicator. The overall reaction is pH
dependent, which determines the indicator color
change at the endpoint, as inferred from the follow
ing equation [21]:
where Inorg is indicator in organic phase;  and 
are hydrogen ion and titrant, respectively, in aqueous
phase.
From the equilibrium constant,  the color
change of the indicator, expressed by the indicator
quotient,  depends upon the hydrogen ion
activity ( ) or pH of the aqueous phase, as shown
below:
Sven et al. [21] concluded that it is advisable to use
as low an endpoint quotient as possible, since broad
ening of the endpoint interval will give opportunities
to improve the titration conditions, and at the same
time titration at pH < 1 cannot be recommended
owing to the difficulties in determining pH in this
range with sufficient precision. The optimum pH for
the SLSISX ion association complex formation rela
tive to the minimum indicator quotient was found to
be 2.5. The positive systematic error due to indicator
quotient was compensated for by performing a blank
titration. In contrast to the formation of indicator
SLS ion pair at the endpoint as proposed by Sven
et al. [21], we postulate the solubilization of dodecyl
sulfuric acid in the organic phase, thereby protonating
dimethyl yellow into a quinoide form (pink in color)
and the protonated dye remained stable in the pres
ence of SLS– as counter ion in the organic phase, as
shown below:
This is supported by decrease in hydrogen ion con
centration from the initial 3 × 10–3 to 2 × 10–3 M at the
end point in the aqueous phase.
Method B was successfully applied to the determi
nation of ISX in spiked human urine sample and injec
tion. Two drops of 2 M H2SO4 is essential to acquire a
pH 2.5 of the aqueous phase prior to titration in the
case of spiked human urine sample. We predict that
this low volume of H2SO4 has the advantage of incom
plete protonation of urea content in the urine which
might compete with ISX.
METHOD VALIDATION
Method validations were done according to the
present ICH guidelines [22].
Selectivity. The proposed methods were tested for
selectivity by placebo blank and synthetic mixture
analyses. A placebo blank containing talc (20 mg),
starch (15 mg), lactose (5 mg), calcium carbonate
(10 mg), calcium dihydrogenorthophosphate (10 mg),
methyl cellulose (5 mg), sodium alginate (15 mg) and
magnesium stearate (10 mg) was prepared, extracted
with respective solvent mentioned under two different
methods and solution made as described under “Pro
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cedure for tablets”. A convenient aliquot of solution
was subjected to analysis by titrimetry according to the
recommended procedures. In both the cases, the
titrant consumption was the same as the blank.
A separate experiment was performed with syn
thetic mixture. To the placebo blank of similar compo
sition, 100 or 200 mg of ISX was added, homogenized
and the solution of the synthetic mixture was prepared
as described under “Procedure for tablets”. 5 mL of
the resulting solution was assayed (n = 5) which
yielded a percent recovery of 105.3 ± 0.75 – 101.0 ±
0.23. These results complement the findings of the
placebo blank analysis with respect to selectivity.
Accuracy and precision. The accuracy of the pro
posed methods was determined by performing repli
cate determinations. The intraday and interday vari
ation in the analysis of ISX was measured at three dif
ferent levels. The accuracy of an analytical method
expresses the closeness between the reference and the
found value. Accuracy was evaluated as percentage
relative error between the measured and taken
amounts/concentrations. The precision of the meth
ods was evaluated in terms of intermediate precision
(intraday and interday). Three different amounts of
ISX within the range in each method were analysed in
seven replicates during the same day (intraday preci
sion) and five consecutive days (interday precision).
The results of these studies are tabulated (Table 1).
Ruggedness. Method ruggedness was expressed as
the RSD of the same procedure applied by four differ
ent analysts as well as using three different burettes.
The interanalyst RSD were within 1.1–2.0% whereas
the interburettes RSD for the same ISX concentra
tions ranged from 2.1–2.3% suggesting that the devel
oped method was rugged.
Application to tablets, spiked human urine and
injection analysis. Commercial ISX tablets were anal
ysed using the developed methods and also by official
method [2] (reference method). The method involves
measurement of aqueous solution of ISX at 300 nm.
The results obtained were compared statistically by the
Student’s ttest and the varianceratio Ftest. The cal
culated t and Fvalues did not exceed the tabulated
values at the 95% confidence level for four degrees of
freedom, indicating close similarity between the pro
posed methods and the reference method with respect
to accuracy and precision. These results are summa
rized in Table 2. The method B was successfully
applied to the determination of ISX in spiked human
urine sample and injection with mean percent recov
ery of 102.5 ± 0.1 (n = 5) and 101.6 ± 1.3 (n = 5),
respectively.
Table 1. Evaluation of intraday and interday accuracy and precision
Method ISX taken, mg
Intraday accuracy and precision Interday accuracy and precision
ISX found, mg RE, % RSD, % ISX found, mg RE, % RSD, %
A
5.00 5.06 1.2 2.7 5.070 1.4 1.1
10.00 9.92 0.8 1.6 10.17 1.7 2.1
15.00 14.92 0.5 0.6 15.41 2.7 2.0
B
2.00 2.05 2.5 0.3 2.031 1.6 1.0
5.00 5.10 2.0 1.4 5.105 2.1 1.2
8.00 8.05 0.6 0.4 8.082 1.0 0.9
Table 2. Results of analysis of tablets by the proposed methods
Tablets analysed Label claim, mg/tablet
Found* (percent label claim ±SD)
Reference method Method A Method B
101.5 ± 1.1 100.4 ± 0.7
Tidilana 20 100.1 ± 1.4 t = 1.77 t = 0.46 
F = 1.61 F = 4.24
101.8 ± 1.2 102.0 ± 1.0
Tidilana 40 102.8 ± 1.1 t = 1.34 t = 1.20
F = 1.21 F = 1.31
* Mean value of three determinations.
Marketed by: a Juggat Pharma, Bangalore, 560074 India.
Tabulated tvalue at the 95% confidence level is 2.78; Tabulated Fvalue at the 95% confidence level is 6.39.
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Recovery study. To further ascertain the accuracy
and reliability of the methods, recovery experiments
were performed via standardaddition procedure. Pre
analysed tablet powder was spiked with pure ISX at
three different levels, and the total was found by the
proposed methods. Each determination was repeated
three times. The percent recovery of pure ISX added
(Table 3) was within the permissible limits indicating
the absence of inactive ingredients in the assay.
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Table 3. Accuracy assessment by recovery experiments
Tablet 
studied
 Method A Method B
ISX
in tablet, 
mg
ISX
in tablet, 
mg*
Pure ISX 
added,
 mg
Total 
found, 
mg
Pure ISX 
recovered*, 
percent ± SD
ISX 
in tablet, 
mg
Pure ISX 
added, 
mg
Total 
found, 
mg
Pure ISX 
recovered*, 
percent ± SD
5.08 2.50 7.79 108.5 ± 0.09 2.69 1.50 4.18 99.34 ± 0.07
Tidilan  20.0 5.08 5.00 10.2 103.2 ± 0.08 2.69 3.00 5.63 98.11 ± 0.06
5.08 10.0 14.9 99.3 ± 0.2  2.69 4.50 6.23 101.3 ± 0.07
4.10 2.00 6.15 102.5 ± 1.0 2.17 1.00 3.18 101.0 ± 1.0
Tidilan 40.0 4.10 4.00 8.15 101.2 ± 0.2 2.17 2.00 4.17 100.0 ± 0.2
4.10 6.00 10.13 100.5 ± 1.1 2.17 3.00 5.22 101.7 ± 1.1
* Mean value of three determinations.
